Rovio Entertainment Corp.
Rovio Entertainment Corporation Stock Exchange Release January 8, 2021 at 10 a.m. EET
Changes in the holding of company’s own shares
Rovio Entertainment Corporation has on January 7, 2021 transferred without consideration a total of 29 527 Company's own shares to Company's management team member based on the Company's share-based incentive scheme.
Following the transfer, Company holds total of 7 819 808 its own shares.
ROVIO ENTERTAINMENT CORPORATION
More information:
Rene Lindell, CFO
RovioIR@rovio.com
Media desk: +358 40 4858985
Distribution:
Nasdaq Helsinki Ltd
Key media
https://investors.rovio.com/en
About Rovio:
Rovio Entertainment Corporation is a global, mobile-first games company that creates, develops and publishes mobile games, which have been downloaded over 4.5 billion times so far. Rovio is best known for the global Angry Birds brand, which started as a popular mobile game in 2009, and has since evolved from games to various entertainment and consumer products in brand licensing. Today, Rovio offers multiple mobile games, animations and produced The Angry Birds Movie in 2016. Its sequel, The Angry Birds Movie 2, was released in 2019. Rovio is headquartered in Finland and the company's shares are listed on the main list of NASDAQ Helsinki stock exchange with the trading code ROVIO. (www.rovio.com)
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ALK Abello19.12.2025 22:46:46 CET | Press release
Major shareholder announcement
ALK Abello19.12.2025 22:46:46 CET | Pressemeddelelse
Storaktionærmeddelelse
Zealand Pharma19.12.2025 22:00:00 CET | Press release
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Boehringer Ingelheim Limited19.12.2025 21:10:00 CET | Press release
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
Novartis Pharma AG19.12.2025 20:30:06 CET | Press release
Novartis and US government reach agreement on lowering drug prices in the US
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
